Table 3 PRS and association with MBL subtypes and CLL among individuals of European ancestry.
PRSb | Controlsc | LC-MBL | HC-MBL | CLL | LC-MBL vs controls | HC-MBL vs Controls | CLL vs Controls | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N = 2631 | N = 396 | N = 164 | N = 696 | ||||||||||||||
N | % | N | % | N | % | N | % | ORa | 95% CI | P | ORa | 95% CI | P | ORa | 95% CI | P | |
Q1 [4.32, 6.80) | 597 | 22% | 41 | 10% | 9 | 6% | 35 | 5% | 0.51 | 0.34–0.76 | 0.001 | 0.33 | 0.15–0.70 | 0.004 | 0.31 | 0.21–0.46 | 1.0 × 10−8 |
Q2 [6.80, 7.32) | 528 | 20% | 62 | 16% | 28 | 17% | 71 | 10% | 0.81 | 0.57–1.17 | 0.27 | 1.05 | 0.61–1.82 | 0.85 | 0.65 | 0.47–0.90 | 0.01 |
Q3 [7.32, 7.77) | 553 | 21% | 76 | 19% | 27 | 16% | 112 | 16% | 1 | Reference | 1 | Reference | 1 | Reference | |||
Q4 [7.77, 8.28) | 463 | 18% | 82 | 21% | 28 | 17% | 142 | 20% | 1.33 | 0.95–1.88 | 0.1 | 1.31 | 0.76–2.26 | 0.34 | 1.56 | 1.17–2.08 | 0.002 |
Q5 [8.28, 11.31) | 490 | 19% | 135 | 34% | 72 | 44% | 336 | 49% | 2.10 | 1.53–2.88 | 4.0 × 10−6 | 3.13 | 1.97–4.98 | 1.0 × 10−6 | 3.49 | 2.70–4.51 | 1.2 × 10−21 |
Continuous | 1.75 | 1.55–1.98 | 7.5 × 10−19 | 2.14 | 1.80–2.56 | 3.9 × 10−17 | 2.53 | 2.27–2.81 | 4.0 × 10−63 | ||||||||
Continuous unweighted | 1.14 | 1.11–1.17 | 1.3 × 10−20 | 1.19 | 1.14–1.23 | 1.9 × 10−17 | 1.23 | 1.20–1.26 | 4.1 × 10−65 | ||||||||
PRS (median) | 7.46 | 7.84 | 8.05 | 8.24 | |||||||||||||
c-statistic | 0.72 | 0.70–0.75 | 0.73 | 0.69–0.77 | 0.77 | 0.75–0.79 | |||||||||||
c-statistic unweighted | 0.72 | 0.70–0.75 | 0.725 | 0.69–0.77 | 0.775 | 0.76–0.79 |